Document is current
Any future updates will be listed below
-
Authors
Fanelli, Giuseppe https://orcid.org/0000-0001-7930-563X
Franke, Barbara https://orcid.org/0000-0003-4375-6572
De Witte, Ward
Ruisch, I. Hyun
Haavik, Jan https://orcid.org/0000-0001-7865-2808
van Gils, Veerle https://orcid.org/0000-0001-8240-5367
Jansen, Willemijn J.
Vos, Stephanie J. B.
Lind, Lars
Buitelaar, Jan K. https://orcid.org/0000-0001-8288-7757
Banaschewski, Tobias https://orcid.org/0000-0003-4595-1144
Dalsgaard, Søren https://orcid.org/0000-0003-4659-0969
Serretti, Alessandro https://orcid.org/0000-0003-4363-3759
Mota, Nina Roth https://orcid.org/0000-0003-3504-759X
Poelmans, Geert https://orcid.org/0000-0001-7039-6985
Bralten, Janita https://orcid.org/0000-0003-1440-8675
-
Funding
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (847879)
- License Information
-
More Information
Article History
Received: 10 June 2021
Revised: 29 December 2021
Accepted: 17 January 2022
First Online: 14 February 2022
Competing interests
: AS is or has been a consultant/speaker for Abbott, Abbvie, Angelini, AstraZeneca, Clinical Data, Boehringer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Innovapharma, Italfarmaco, Janssen, Lundbeck, Naurex, Pfizer, Polifarma, Sanofi, and Servier. BF discloses having received educational speaking fees from Medice. GP is director of Drug Target ID (DTID), Ltd. JH discloses having received educational speaking fees from Medice, Takeda/Shire, and Biocodex. JKB has been in the past three years a consultant to/member of the advisory board of/and/or speaker for Takeda/Shire, Roche, Medice, Angelini, Janssen, and Servier. All other authors report no biomedical financial interests or potential conflicts of interest.
